BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 31210410)

  • 1. LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma.
    Sui C; Dong Z; Yang C; Zhang M; Dai B; Geng L; Lu J; Yang J; Xu M
    J Cell Mol Med; 2019 Sep; 23(9):6024-6033. PubMed ID: 31210410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1.
    Zhou Y; Huang Y; Dai T; Hua Z; Xu J; Lin Y; Han L; Yue X; Ho L; Lu J; Ai X
    Biomed Pharmacother; 2021 Jan; 133():111030. PubMed ID: 33378944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway.
    Gao J; Dai C; Yu X; Yin XB; Zhou F
    J Cell Biochem; 2021 Jan; 122(1):86-99. PubMed ID: 32786108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
    Chen YT; Xiang D; Zhao XY; Chu XY
    Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363.
    Huang H; Chen J; Ding CM; Jin X; Jia ZM; Peng J
    J Cell Mol Med; 2018 Jun; 22(6):3238-3245. PubMed ID: 29602203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells.
    Li W; Dong X; He C; Tan G; Li Z; Zhai B; Feng J; Jiang X; Liu C; Jiang H; Sun X
    J Exp Clin Cancer Res; 2019 May; 38(1):183. PubMed ID: 31053148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis.
    Wang Y; Yang L; Chen T; Liu X; Guo Y; Zhu Q; Tong X; Yang W; Xu Q; Huang D; Tu K
    Mol Cancer; 2019 Feb; 18(1):28. PubMed ID: 30782188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long non-coding RNA F11-AS1 inhibits HBV-related hepatocellular carcinoma progression by regulating NR1I3 via binding to microRNA-211-5p.
    Deng Y; Wei Z; Huang M; Xu G; Wei W; Peng B; Nong S; Qin H
    J Cell Mol Med; 2020 Jan; 24(2):1848-1865. PubMed ID: 31880390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p.
    Chen BW; Zhou Y; Wei T; Wen L; Zhang YB; Shen SC; Zhang J; Ma T; Chen W; Ni L; Wang Y; Bai XL; Liang TB
    J Cell Biochem; 2021 Jan; 122(1):130-142. PubMed ID: 32951268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long Noncoding RNA (lncRNA) FOXD2-AS1 Promotes Cell Proliferation and Metastasis in Hepatocellular Carcinoma by Regulating MiR-185/AKT Axis.
    Chen Z; Zhang Z; Zhao D; Feng W; Meng F; Han S; Lin B; Shi X
    Med Sci Monit; 2019 Dec; 25():9618-9629. PubMed ID: 31841454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candidate lncRNA-miRNA-mRNA network in predicting hepatocarcinogenesis with cirrhosis: an integrated bioinformatics analysis.
    Zhang R; Jiang YY; Xiao K; Huang XQ; Wang J; Chen SY
    J Cancer Res Clin Oncol; 2020 Jan; 146(1):87-96. PubMed ID: 31758243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of lncRNA PTOV1-AS1 in hepatocellular carcinoma contributes to disease progression and sorafenib resistance through regulating miR-505.
    Chi X; Chen Z; Chen Y; Hong H; Yu J; Lv L
    J Biochem Mol Toxicol; 2023 Oct; 37(10):e23437. PubMed ID: 37352125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. lncRNA KRAL reverses 5-fluorouracil resistance in hepatocellular carcinoma cells by acting as a ceRNA against miR-141.
    Wu L; Pan C; Wei X; Shi Y; Zheng J; Lin X; Shi L
    Cell Commun Signal; 2018 Aug; 16(1):47. PubMed ID: 30119680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long non-coding RNA SBF2-AS1 promotes hepatocellular carcinoma progression through regulation of miR-140-5p-TGFBR1 pathway.
    Li Y; Liu G; Li X; Dong H; Xiao W; Lu S
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2826-2832. PubMed ID: 30115383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long noncoding RNA FOXD2-AS1 aggravates hepatocellular carcinoma tumorigenesis by regulating the miR-206/MAP3K1 axis.
    Hu W; Feng H; Xu X; Huang X; Huang X; Chen W; Hao L; Xia W
    Cancer Med; 2020 Aug; 9(15):5620-5631. PubMed ID: 32558350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing lncRNA FOXD2-AS1 inhibits proliferation, migration, invasion and drug resistance of drug-resistant glioma cells and promotes their apoptosis via microRNA-98-5p/CPEB4 axis.
    Gu N; Wang X; Di Z; Xiong J; Ma Y; Yan Y; Qian Y; Zhang Q; Yu J
    Aging (Albany NY); 2019 Nov; 11(22):10266-10283. PubMed ID: 31770107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway.
    Lei T; Zhu X; Zhu K; Jia F; Li S
    Cancer Biol Ther; 2019; 20(7):1007-1016. PubMed ID: 30929558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing of long noncoding RNA LEF1-AS1 prevents the progression of hepatocellular carcinoma via the crosstalk with microRNA-136-5p/WNK1.
    Dong H; Jian P; Yu M; Wang L
    J Cell Physiol; 2020 Oct; 235(10):6548-6562. PubMed ID: 32068261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FoxD2-AS1 promotes glioma progression by regulating miR-185-5P/HMGA2 axis and PI3K/AKT signaling pathway.
    Ni W; Xia Y; Bi Y; Wen F; Hu D; Luo L
    Aging (Albany NY); 2019 Mar; 11(5):1427-1439. PubMed ID: 30860979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The lncRNA lnc-TSI antagonizes sorafenib resistance in hepatocellular carcinoma via downregulating miR-4726-5p expression and upregulating KCNMA1 expression.
    Chen F; Jiang J; Liu D; Li H; Dong L; Song Y; Zhang Y; Wang J; Qin Y; Zhao G
    J Mol Histol; 2024 Feb; 55(1):83-96. PubMed ID: 38165571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.